JP2017506237A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506237A5
JP2017506237A5 JP2016551851A JP2016551851A JP2017506237A5 JP 2017506237 A5 JP2017506237 A5 JP 2017506237A5 JP 2016551851 A JP2016551851 A JP 2016551851A JP 2016551851 A JP2016551851 A JP 2016551851A JP 2017506237 A5 JP2017506237 A5 JP 2017506237A5
Authority
JP
Japan
Prior art keywords
dimethyl
tetrahydropyridin
trifluoro
amino
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016551851A
Other languages
English (en)
Japanese (ja)
Other versions
JP6483146B2 (ja
JP2017506237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053327 external-priority patent/WO2015124576A1/en
Publication of JP2017506237A publication Critical patent/JP2017506237A/ja
Publication of JP2017506237A5 publication Critical patent/JP2017506237A5/ja
Application granted granted Critical
Publication of JP6483146B2 publication Critical patent/JP6483146B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016551851A 2014-02-19 2015-02-17 アルツハイマー病治療用のbace1阻害剤としての2−アミノ−3,5,5−トリフルオロ−3,4,5,6−テトラヒドロピリジン Expired - Fee Related JP6483146B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201400086 2014-02-19
DKPA201400086 2014-02-19
DKPA201400349 2014-07-01
DKPA201400349 2014-07-01
PCT/EP2015/053327 WO2015124576A1 (en) 2014-02-19 2015-02-17 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2017506237A JP2017506237A (ja) 2017-03-02
JP2017506237A5 true JP2017506237A5 (enExample) 2018-03-29
JP6483146B2 JP6483146B2 (ja) 2019-03-13

Family

ID=59009438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551851A Expired - Fee Related JP6483146B2 (ja) 2014-02-19 2015-02-17 アルツハイマー病治療用のbace1阻害剤としての2−アミノ−3,5,5−トリフルオロ−3,4,5,6−テトラヒドロピリジン

Country Status (25)

Country Link
US (2) US20170066741A1 (enExample)
EP (1) EP3107897A1 (enExample)
JP (1) JP6483146B2 (enExample)
KR (1) KR20160115936A (enExample)
CN (1) CN106029639B (enExample)
AP (1) AP2016009370A0 (enExample)
AR (1) AR099489A1 (enExample)
AU (1) AU2015220873A1 (enExample)
CA (1) CA2940028A1 (enExample)
CL (1) CL2016002072A1 (enExample)
CR (1) CR20160352A (enExample)
DO (1) DOP2016000194A (enExample)
EA (1) EA031132B1 (enExample)
EC (1) ECSP16072941A (enExample)
GE (1) GEP20186892B (enExample)
IL (1) IL246875A0 (enExample)
MA (1) MA39225A1 (enExample)
MX (1) MX2016010777A (enExample)
PE (1) PE20161225A1 (enExample)
PH (1) PH12016501600A1 (enExample)
RU (1) RU2016133626A (enExample)
SG (1) SG11201606812WA (enExample)
TW (1) TW201609700A (enExample)
UA (1) UA117695C2 (enExample)
WO (1) WO2015124576A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029639B (zh) 2014-02-19 2019-01-08 H.隆德贝克有限公司 治疗阿尔茨海默病的bace1抑制剂的2-氨基-3,5,5-三氟-3,4,5,6-四氢吡啶
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) * 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) * 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TW201717948A (zh) 2015-08-10 2017-06-01 H 朗德貝克公司 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療
US10011596B2 (en) * 2015-08-12 2018-07-03 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
WO2017044807A2 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
TW201726651A (zh) * 2015-09-23 2017-08-01 健生藥品公司 2,3,4,5-四氫吡啶-6-胺衍生物
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CA3041595A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
WO2018078038A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
WO2018114910A1 (en) 2016-12-21 2018-06-28 H. Lundbeck A/S 6-amino-5-fluoro-5-(fluoromethyl)-2,3,4,5-tetrahydropyridin-2-yl-phenyl-5-(methoxy-d3)-pyrazine-2-carboxamides and fluorinated derivatives thereof as bace1 inhibitors
UY37918A (es) 2017-10-05 2019-04-30 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR20200099154A (ko) 2017-12-14 2020-08-21 하. 룬드벡 아크티에셀스카브 1H-피라졸로[4,3-b]피리딘의 투여를 포함하는 조합 치료제
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
KR102507861B1 (ko) 2018-04-19 2023-03-09 삼성에스디에스 주식회사 부채널 공격에 안전한 연산 장치 및 방법
KR102510077B1 (ko) 2018-04-24 2023-03-14 삼성에스디에스 주식회사 부채널 공격에 안전한 연산 장치 및 방법
US12042492B2 (en) 2020-10-09 2024-07-23 Texas Tech University System BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
GB0124928D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
SI1474395T1 (sl) * 2002-02-12 2008-02-29 Smithkline Beecham Corp Nikotinamidni derivati, uporabni kot inhibitorji p38
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
EP2580200B1 (en) * 2010-06-09 2016-09-14 Janssen Pharmaceutica, N.V. 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
CN103261199A (zh) * 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
CA2824097A1 (en) * 2011-01-12 2012-07-19 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
MA34898B1 (fr) * 2011-01-13 2014-02-01 Novartis Ag Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
US8754075B2 (en) * 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
WO2012147763A1 (ja) * 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するbace1阻害剤
WO2012168164A1 (en) * 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
UY34278A (es) * 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
US8338413B1 (en) * 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
WO2013142613A1 (en) 2012-03-20 2013-09-26 Elan Pharmaceuticals, Inc. Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
WO2014056816A1 (en) 2012-10-10 2014-04-17 F. Hoffmann-La Roche Ag COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
AU2014223334C1 (en) 2013-03-01 2018-10-18 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
CN106029639B (zh) 2014-02-19 2019-01-08 H.隆德贝克有限公司 治疗阿尔茨海默病的bace1抑制剂的2-氨基-3,5,5-三氟-3,4,5,6-四氢吡啶
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有bace1抑制活性之二氫噻及二氫衍生物

Similar Documents

Publication Publication Date Title
JP2017506237A5 (enExample)
RU2016133626A (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
RU2017116197A (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2019517455A5 (enExample)
JP2017538750A5 (enExample)
RU2021127810A (ru) Замещенные гетероарилом пиридины и способы применения
RU2501791C2 (ru) Производное триазола или его соль
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
JP2013539774A5 (enExample)
JP2015509510A5 (enExample)
RU2017125520A (ru) Соединения, ингибирующие parg
JP2012530705A5 (enExample)
JP2013519680A5 (enExample)
JP2011500679A5 (enExample)
JP2016540811A5 (enExample)
JP2016534124A5 (enExample)
JP2016523963A5 (enExample)
JP2005517006A5 (enExample)
JP2013527847A5 (enExample)
HRP20191554T1 (hr) Derivat azol benzena
RU2015104962A (ru) Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков
JP2017509676A5 (enExample)
JP2013544854A5 (enExample)